Development of DNA Aptamers to Native EpCAM for Isolation of Lung Circulating Tumor Cells from Human Blood

Zamay, Galina S.; Kolovskaya, Olga S.; Ivanchenko, Tatiana I.; Zamay, Tatiana N.; Veprintsev, Dmitry V.; Grigorieva, Valentina; Garanzha, Irina I; Krat, Alexey V.; Glazyrin, Yury E.; Gargaun, Ana; Лапин, И. Н.; Svetlichnyi, V. A.; Berezovski, Maxim V.; Kichkailo, Anna S.

doi:10.3390/cancers11030351

Cited by 20 publications

(18 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The great supremacy in development of technology for new aptamers and second generation analogs, such as X‐Aptamers (XAs), SOMAmers, locked nucleic acids (LNAs), suggests aptamers are promising as a theranostic tool in clinical setting in near future. Recently, DNA aptamers were selected against EpCAM expressed on primary lung cancer cells, and then successfully applied to isolation and detection of circulating tumor cells in blood samples of lung cancer patients . Aptamers have also been used to design electrochemical aptamer‐based biosensors for the detection of specific cancer cell markers in blood samples …”

Section: Aptamer Emerges As a Prominent Targeting Ligand For Nanodelimentioning

confidence: 99%

Exosomes and Nanoengineering: A Match Made for Precision Therapeutics

et al. 2019

View full text Add to dashboard Cite

Intense efforts from both scientists and physicians across Australia have been devoted onward advancing studies to fill the gap in understanding the biology and pathogenesis underlying cancer development. Exosomes are membrane-bound bio-nanoparticles secreted or released by most cells into the extracellular space. There has been an increasing interest in such bio-nanoparticles over the past 10 years, evident from the publication number of only 324 papers in 2006 to a massive increase to 4603 publications in 2018 with the search term "exosome" based on title/abstract in PubMed. Among these studies, 151 articles published from 2007 to 2018 are from Australian institutions, with 33 papers published in 2018. Such a strong surge of interest is due to discoveries that exosomes play key roles in intercellular and intertissue communication mediated by virtue of cargos contained inside the membrane-confined space. Furthermore, exosome cargos, including proteins, mRNAs and miRNAs, are linked to the Targeted exosomal delivery systems for precision nanomedicine attract wide interest across areas of molecular cell biology, pharmaceutical sciences, and nanoengineering. Exosomes are naturally derived 50-150 nm nanovesicles that play important roles in cell-to-cell and/or cell-to-tissue communications and cross-species communication. Exosomes are also a promising class of novel drug delivery vehicles owing to their ability to shield their payload from chemical and enzymatic degradations as well as to evade recognition by and subsequent removal by the immune system. Combined with a new class of affinity ligands known as aptamers or chemical antibodies, molecularly targeted exosomes are poised to become the next generation of smartly engineered nanovesicles for precision medicine. Here, recent advances in targeted exosomal delivery systems engineered by aptamer for future strategies to promote human health using this class of human-derived nanovesicles are summarized.The ORCID identification number(s) for the author(s) of this article can be found under https://doi.

show abstract

Section: Aptamer Emerges As a Prominent Targeting Ligand For Nanodelimentioning

confidence: 99%

Exosomes and Nanoengineering: A Match Made for Precision Therapeutics

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Aptamers are a kind of small oligonucleotides (e.g., DNA, RNA, or peptides) with the ease of binding to molecular and cellular components . Furthermore, they are easily synthesized and separated with high sensitivity and specificity through a systematic evolution of ligands by exponential enrichment (SELEX) process which is the key feature of aptamers used for CTCs' isolation . Hence, the aptamer‐functionalized nanostructures were introduced to increase topographic interactions between targeted CTCs and surface coated with specific antibodies, giving rise to recovered CTCs' isolation with satisfactory capture efficiency …”

Section: D Microfluidic Platforms For Ctcs' Detection and Isolationmentioning

confidence: 99%

Recent Advances in Microfluidic Platforms Applied in Cancer Metastasis: Circulating Tumor Cells' (CTCs) Isolation and Tumor‐On‐A‐Chip

Lin

Luo

et al. 2019

Small

View full text Add to dashboard Cite

Cancer remains the leading cause of death worldwide despite the enormous efforts that are made in the development of cancer biology and anticancer therapeutic treatment. Furthermore, recent studies in oncology have focused on the complex cancer metastatic process as metastatic disease contributes to more than 90% of tumor‐related death. In the metastatic process, isolation and analysis of circulating tumor cells (CTCs) play a vital role in diagnosis and prognosis of cancer patients at an early stage. To obtain relevant information on cancer metastasis and progression from CTCs, reliable approaches are required for CTC detection and isolation. Additionally, experimental platforms mimicking the tumor microenvironment in vitro give a better understanding of the metastatic microenvironment and antimetastatic drugs' screening. With the advancement of microfabrication and rapid prototyping, microfluidic techniques are now increasingly being exploited to study cancer metastasis as they allow precise control of fluids in small volume and rapid sample processing at relatively low cost and with high sensitivity. Recent advancements in microfluidic platforms utilized in various methods for CTCs' isolation and tumor models recapitulating the metastatic microenvironment (tumor‐on‐a‐chip) are comprehensively reviewed. Future perspectives on microfluidics for cancer metastasis are proposed.

show abstract

“…In addition to differential approaches, whole-living cell-based protocols have been applied by the same group for the selection of aptamers against NSCLC-related known targets [ 20 ]. The authors addressed the selection of DNA aptamers against the epithelial cell adhesion molecule (EpCAM), a marker expressed at high levels by many carcinomas as well as by circulating tumor cells [ 21 , 22 ].…”

Section: Selex Technologies To Generate Nsclc Targeting Aptamersmentioning

confidence: 99%

“…The possibility to use aptamers for the detection of CTCs was also described by Zamay et al [ 19 , 20 ]. They found that fluorescently labeled aptamers selected against lung adenocarcinoma cells from postoperative tissues, when applied to patients’ peripheral blood samples, were able to detect CTCs, with a specificity of 76% and a sensitivity of 86% [ 19 ].…”

Section: Nucleic Acid Aptamers For Nsclc Detectionmentioning

confidence: 99%

“…They found that fluorescently labeled aptamers selected against lung adenocarcinoma cells from postoperative tissues, when applied to patients’ peripheral blood samples, were able to detect CTCs, with a specificity of 76% and a sensitivity of 86% [ 19 ]. More recently, the same authors used two DNA aptamers (ECM-APT-01 and ECM-APT-02) directed against EpCAM to isolate and detect EpCAM + CTCs in clinical blood samples with a detection limit of 0–2 cells/mL of blood [ 20 ]. Further, Vidic and colleagues demonstrated that an aptamer (A155_18) isolated by cell-SELEX (see previous section for details) showed a good potential as a diagnostic tool for the detection of NSCLC CTCs expressing the stem cell marker CD90 [ 15 ].…”

Section: Nucleic Acid Aptamers For Nsclc Detectionmentioning

confidence: 99%

See 1 more Smart Citation

Advances in Oligonucleotide Aptamers for NSCLC Targeting

Rotoli

Santana-Viera

Ibba

et al. 2020

IJMS

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer worldwide, with the highest incidence in developed countries. NSCLC patients often face resistance to currently available therapies, accounting for frequent relapses and poor prognosis. Indeed, despite great recent advancements in the field of NSCLC diagnosis and multimodal therapy, most patients are diagnosed at advanced metastatic stage, with a very low overall survival. Thus, the identification of new effective diagnostic and therapeutic options for NSCLC patients is a crucial challenge in oncology. A promising class of targeting molecules is represented by nucleic-acid aptamers, short single-stranded oligonucleotides that upon folding in particular three dimensional (3D) structures, serve as high affinity ligands towards disease-associated proteins. They are produced in vitro by SELEX (systematic evolution of ligands by exponential enrichment), a combinatorial chemistry procedure, representing an important tool for novel targetable biomarker discovery of both diagnostic and therapeutic interest. Aptamer-based approaches are promising options for NSCLC early diagnosis and targeted therapy and may overcome the key obstacles of currently used therapeutic modalities, such as the high toxicity and patients’ resistance. In this review, we highlight the most important applications of SELEX technology and aptamers for NSCLC handling.

show abstract

Development of DNA Aptamers to Native EpCAM for Isolation of Lung Circulating Tumor Cells from Human Blood

Cited by 20 publications

References 20 publications

Exosomes and Nanoengineering: A Match Made for Precision Therapeutics

Exosomes and Nanoengineering: A Match Made for Precision Therapeutics

Recent Advances in Microfluidic Platforms Applied in Cancer Metastasis: Circulating Tumor Cells' (CTCs) Isolation and Tumor‐On‐A‐Chip

Advances in Oligonucleotide Aptamers for NSCLC Targeting

Contact Info

Product

Resources

About